FINANCIAL IMPACT OF INTRODUCING SC TRASTUZUMAB (HERCEPTIN) VERSUS CURRENTLY USED IV TRASTUZUMAB (HERCEPTIN) ON THE BUDGETS OF DIFFERENT HOSPITALS ACROSS KINGDOM OF SAUDI ARABIA (KSA)
Author(s)
N A1, Ali A2, AL-Tweigeri T3, Zekri J4, Awad N5, Safwat M5, Narang A6, Goyal R7
1King Khalid National Guard Hospital, Jeddah, Saudi Arabia, 2King Fahad Medical City, Riyadh, Saudi Arabia, 3King Faisal Specialist Hospital, Riyadh, Saudi Arabia, 4King Faisal Specialist Hospital, Jeddah, Saudi Arabia, 5QuintilesIMS, Dubai, United Arab Emirates, 6QunitilesIMS, Gurugram, India, 7QuintilesIMS, Thane, India
OBJECTIVES: Trastuzumab is the standard of care in HER2+ve breast cancer (BC) treatment. It is usually administered as intravenous (IV) infusion. This study investigated economic implications of using subcutaneous (SC) trastuzumab compared to IV formulation in KSA for early BC (EBC). METHODS: A budget impact model was developed to estimate financial impact of introducing fixed dose trastuzumab SC for treatment of HER2+ve EBC in KSA. Clinical and cost inputs were obtained through discussion with medical oncologists and hematologists. Base case scenario evaluated impact of replacing IV formulation by SC in 100% patients in 1st year itself and impact of gradual replacement of IV formulation by SC in up to 75% patients (SC adoption in Year 1: 25%; Year 2: 50%; Year 3: 75%). Two hypothetical scenarios evaluated impact of reduction in non-drug cost (by 25% and 50% in scenario 1 and 2 respectively) based on increased awareness and higher use of SC trastuzumab in local treatment centers. RESULTS: Introduction of trastuzumab SC vials across different hospitals in KSA is expected to lead to cost savings by decreasing total cost by 1.6% to 3.1%. For the scenario considering gradual replacement, reduction in total budget across KSA for Year 1, ranged from 0.4%-0.8%; for Year 2, ranged from 0.8%-1.6% and for Year 3, ranged from 1.2%-2.3%. In hypothetical scenarios, the reduction in total cost ranged from 7.2% to 9.4% and 12.4% to 16.6% in scenarios 1 and 2 respectively. Fixed dose SC formulation led to lower drug cost due to elimination of vial wastage. Lower monitoring time and ability to administer at local treatment center lowered non-drug cost compared to IV formulation given at major hospitals. CONCLUSIONS: Trastuzumab SC reduces the overall treatment cost as compared to trastuzumab IV due to less hospitalization and travel costs thus decreasing the budgetary impact in KSA.
Conference/Value in Health Info
2017-11, ISPOR Europe 2017, Glasgow, Scotland
Value in Health, Vol. 20, No. 9 (October 2017)
Code
PCN60
Topic
Economic Evaluation
Topic Subcategory
Budget Impact Analysis
Disease
Oncology